In referanse to the Stock Exchange announcement on 2 November 2020 (below) where an abstract of the publication was available. […]
Other News |
Press Releases
BioStock has done a piece on Ultimovacs’ main advancements in the Q3-2020 period
“Ultimovacs is developing a universal cancer vaccine with the aim of inducing an immune response in cancer patients that is […]
Interview with Carlos de Sousa in Nordic Life Science magazine
“In June this year, Carlos de Sousa commenced his role as Chief Executive Officer of Norwegian Ultimovacs, a pharmaceutical company […]
Sara Mangsbo recieves 2020 SITC Team Science Award
As SITC celebrates 35 years of advancing the field of cancer immunotherapy, they want to recognize and honor those that […]
Upcoming conferences
Ultimovacs’ management team, including CEO Carlos de Sousa, will be participating in three upcoming conferences in the following weeks. Ultimovacs’ […]
BioStock has published the article: “Ultimovacs in the fight against Melanoma”
“Melanoma is the deadliest form of skin cancer. As such, new treatments for the disease are in strong demand. Norwegian […]
Article in HealthTalk covering the Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patients
“Ultimovacs med lovende overlevelsesdata på pasienter med føflekkreft som fikk kreftvaksinen UV1 i kombinasjon med immunterapi Ultimovacs har nå gått […]
BioStock has published an in-depth article on Ultimovacs
“Cancer’s heavy burden on society has created a strong demand for new innovative therapeutic solutions. Over the last decade, immunotherapy […]
Article in Asbestos.com on the NIPU trial
Asbestos.com this week published an article about the NIPU trial in which Ultimovacs’ universal cancer vaccine UV1 will be investigated in […]